ConforMIS (NASDAQ:CFMS) Rating Change
ConforMIS (NASDAQ:CFMS)’s Stock was downgraded to Underweight by stock research analysts at JPMorgan. CFMS’s Neutral rating is no longer valid.
This stock rating downgrade is noticed by stock traders, as NASDAQ:CFMS is at the moment trading -7.83% lower at $3.53 as of 10:06 AM New York time. ConforMIS’s stock is 0% in the last 200 days. It has underperformed the S&P500, which has gained 6.00% in the same time.
Out of 5 brokers covering ConforMIS, 6 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $12 and the lowest is $8 according to Thomson/First Call. The 12-month mean target is $11.2, which means upside potential of 217.28% over the current price.
ConforMIS (NASDAQ:CFMS) Profile
ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
ConforMIS (NASDAQ:CFMS) traded down -7.83% on 2 January, hitting $3.53. A total of 365,749 shares of the company’s stock traded hands. This is up from average of 274,880 shares. ConforMIS has a 52 week low of $3.22 and a 52 week high of $10.93. The company has a market cap of $158.27M and a P/E ratio of 0.
Get the latest ConforMIS (NASDAQ:CFMS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post ConforMIS (NASDAQ:CFMS) Downgraded to Underweight Rating by JPMorgan from Neutral appeared first on Octafinance.